Why is it important to plan Phase Two: Pharmacology early?

It’s helpful to know upfront which therapies will be tested to avoid delays. It’s important to makes these decision early with the treating oncologist, as procuring these test agents can take time. Certis will need to know how many test arms will be included to determine the number of patient-derived xenograft orthotopic model replicates to create. We enroll five fully tumored mouse avatars in each test arm, including the control arm. By way of example: if an individual chooses to test five different therapeutic options, that is a 6 test arms (5 plus 1 control); 30 fully tumored mouse avatars would be required to conduct the test. We generally engraft 25% more mice than are needed to ensure we have enough avatars when it comes time to begin testing.